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The Euro Heart Survey on valvular heart disease discovered a
large number of patients with severe symptomatic valve dis-
eases, who were not indicated for intervention [1,2]. The reasons
were mainly older age and left ventricular dysfunction. The new
ESC guidelines clearly specify the possibility of surgical or
interventional treatment of high risk patients in experienced
centers. On the other hand, we can see the trend toward early
surgery in asymptomatic patients with severe valvular disease. The
operation before ventricular dilatation and dysfunction improves
early mortality, as well as long-term postoperative survival. It
was the development of echocardiography with detailed non-
invasive evaluation of the valvular pathology and its conse-
quences, which enabled the quick progress in valve-sparing
surgery. The absence of life-long anticoagulation and low surgi-
cal mortality in asymptomatic patients with good ventricular
function facilitates the early indication for surgery.
2. Mitral regurgitation
More detailed criteria for echocardiographic evaluation of the
severity of different valve diseases may be found in the
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jana.popelova@homolka.cz (J. Popelova´).graphy [3–5]. However, the definition of mild and moderate
ischemic (functional, secondary) mitral regurgitation (MR) is difficult
to find, even though the guidelines on valvular disease mention
it. Functional mitral regurgitation is dynamic and depends
predominantly on the shape and function of the left ventricle,
loading conditions and systolic pressure. The criteria for severe
functional ischemic MR (EROA Z20 mm , RV2 Z30 ml) are based
on prognostic data and identify patients with increased risk of
cardiovascular events. Exercise echocardiography may discover
increased severity of the functional MR and should be per-
formed before the planned surgery. Patients with the increase
of EROA by Z13 mm during exercise also have increased risk.2
The optimal approach to patients with ischemic MR who do not
fulfill the criteria of severe ischemic MR (neither at rest nor
during exercise), is not clear and has to be assessed.
There is a different approach to severe asymptomatic primary
MR between the new ESC and ACC/AHA guidelines [6,7].
Patients with severe chronic asymptomatic MR with normal left
ventricular systolic function (EF460%) and left ventricular
end-systolic dimension (LVESD) o40 mm would undergo mitral
valve repair in expert center according the ACC/AHA guidelines,
if there was more than 90% likelihood of successful repair
with no residual MR. In Europe, this patient would have a chance
for repair only in the case of flail leaflet with LVESD Z40 mm.Published by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
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with excellent results of mitral valve repair and low operative
mortality. If there is a clear pathology with severe MR, the
conservative observation can hardly improve the prognosis.
ACEI are not recommended in organic MR without heart
failure, however, they should be used for the treatment of
hypertension in patients with MR.3. Aortic regurgitation
The ESC and ACC/AHA guidelines use the indexed values of heart
chambers and aorta diameters inconsistently. We think that the
indexed values are useful and we recommend its use. The
indexation is usually for body surface area (BSA). The dimen-
sions may be indexed also for height, which might be more
appropriate for obese patients; however the prognostic data for
this type of indexation are missing. In the Czech guidelines we
suggested the cut-off values for intervention in severe asympto-
matic aortic regurgitation (AR) 35 mm/m2 BSA for the end-
diastolic left ventricular dimension and 25 mm/m2 for the
LVESD, to exclude the risk of persistent left ventricular dilata-
tion and dysfunction after operation [8,9]. This is important
especially for women, in whom the increased long-term mor-
tality after aortic valve replacement for AR could be explained
by underestimation of the left ventricular dilatation. We also
should not forget, that left ventricle with increased wall thick-
ness (as a consequence of hypertension, concomitant aortic
stenosis or coarctation) does not dilate even in severe AR.
The ESC guidelines do not mention the indexed values for
the dilatation of ascending aorta. This may be misleading for both
sides of BSA spectrum. For example, a girl with Turner syn-
drome might have BSA of 1.3 m2—her ascending aorta of
40 mm represents 31 mm/m2 BSA. On the other hand, a man
with BSA 2.2 m2 and ascending aorta of 55 mm has indexed
value of 25 mm/m2. Of course, not only the BSA, but also the
proportionality of the size of heart and aorta is important. The
upper limit for aortic bulbus is 21 mm/m2 BSA; dilatation has
been defined as 50% increase, that means 31.5 mm/m2 [6,7].
The possible cut-off value for aortic surgery of the ascending
aorta is the indexed value of 25 mm/m2, especially in bicuspid
aortic valves, according to the ACC/AHA guidelines [6,7]. In
patients after coarctation repair, the intervention is recom-
mended if ascending aorta exceeds the diameter of 27.5 mm/
m2 [10].4. Aortic stenosis
The ESC guidelines define severe aortic stenosis (AS) by AVA
o1 cm2 or 0.6 cm2/m2; however many experienced cardiolo-
gists would prefer the cut-off value of 0.5 cm2/m2 or 0.8 cm2
for the ‘‘really severe’’ AS. Especially, if we consider the
operation of severe asymptomatic AS with normal LVEF, the
AVA should be o0.8 cm2 and the patient should have at least
one of the following characteristics: a positive exercise test,
heavy valve calcifications, rapid progression of AS, excessive
left ventricular hypertrophy or elevated natriuretic peptides
[11]. We think that the exercise test in a patient with severe
AS should be evaluated as abnormal if the blood pressurefalls, but not necessarily below the baseline. The onset of
symptoms may be predicted by the elevation of the natriure-
tic peptides [11].
Patients with low-flow, low-gradient severe AS with pre-
served LVEF have worse prognosis than those with severe AS
with high gradient [12]. The differentiation of the ‘‘paradox-
ical’’ low-flow, low-gradient severe AS with preserved LVEF
from moderate AS is crucial, because the operation improves
long-term survival in low-flow, low-gradient severe AS with
preserved ejection fraction, but not in the moderate AS [12].
The new ESC guidelines define indications for TAVI (trans-
catheter aortic valve implantation) with a great impact on the
heart-team decision. In this way, not only the Euroscore, but
also other factors, e.g. porcelain aorta, history of chest
radiotherapy and other risk factors may individually be taken
into account.5. Anticoagulation therapy
Different approaches can be found between the ESC guidelines
(original full-text) and recommendations for the management
of patients after heart valve surgery [13] in the solution of
increased INR. Butchart does not recommend giving vitamin K if
the patient is not bleeding and INR does not exceed 10, because
of the risk of valve thrombosis if INR falls down rapidly [13]. In a
patient with INR46 oral anticoagulants should be stopped and
the patient should be admitted to the hospital; in case of INR
410, fresh frozen plasma should be considered. In the case of
bleeding with high INR, local control of bleeding, prothrombin
complex or vitamin K may be necessary, even if they increase
the risk of valve thrombosis. In the ESC guidelines the oral
vitamin K in low dose (1–2 mg) is considered a possibility in INR
6–10; in INR 410 the recommended dose is 5 mg. Presently,
there are no sufficient data to recommend new antithrombotic
drugs (direct oral inhibitors of factor IIa or Xa) to patients with
mechanical heart valves.
In conclusion, the ESC guidelines are clear, useful and we
believe that they will help in improving the care of patients
with valvular heart diseases.
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